Mediwound (MDWD) has released an update.
MediWound, a biopharmaceutical company, reports a solid financial position with $51 million in cash and a 2023 revenue of approximately $19 million, driven by the commercial success of its enzymatic debridement products for burn and wound care. The company has announced strategic collaborations and significant milestones, including FDA approvals and a scale-up in manufacturing capabilities to meet global demand. MediWound’s product pipeline is progressing, with ongoing clinical trials and the development of a cost-saving health economic model to facilitate market adoption in the United States.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
